Literature DB >> 23507172

Exercise intolerance in Glycogen Storage Disease Type III: weakness or energy deficiency?

Nicolai Preisler1, Agnès Pradel, Edith Husu, Karen Lindhardt Madsen, Marie-Hélène Becquemin, Alix Mollet, Philippe Labrune, Francois Petit, Jean-Yves Hogrel, Claude Jardel, Francois Maillot, John Vissing, Pascal Laforêt.   

Abstract

Myopathic symptoms in Glycogen Storage Disease Type IIIa (GSD IIIa) are generally ascribed to the muscle wasting that these patients suffer in adult life, but an inability to debranch glycogen likely also has an impact on muscle energy metabolism. We hypothesized that patients with GSD IIIa can experience exercise intolerance due to insufficient carbohydrate oxidation in skeletal muscle. Six patients aged 17-36-years were studied. We determined VO 2peak (peak oxygen consumption), the response to forearm exercise, and the metabolic and cardiovascular responses to cycle exercise at 70% of VO 2peak with either a saline or a glucose infusion. VO 2peak was below normal. Glucose improved the work capacity by lowering the heart rate, and increasing the peak work rate by 30% (108 W with glucose vs. 83 W with placebo, p=0.018). The block in muscle glycogenolytic capacity, combined with the liver involvement caused exercise intolerance with dynamic skeletal muscle symptoms (excessive fatigue and muscle pain), and hypoglycemia in 4 subjects. In this study we combined anaerobic and aerobic exercise to systematically study skeletal muscle metabolism and exercise tolerance in patients with GSD IIIa. Exercise capacity was significantly reduced, and our results indicate that this was due to a block in muscle glycogenolytic capacity. Our findings suggest that the general classification of GSD III as a glycogenosis characterized by fixed symptoms related to muscle wasting should be modified to include dynamic exercise-related symptoms of muscle fatigue. A proportion of the skeletal muscle symptoms in GSD IIIa, i.e. weakness and fatigue, may be related to insufficient energy production in muscle.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23507172     DOI: 10.1016/j.ymgme.2013.02.008

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  12 in total

Review 1.  Skeletal muscle disorders of glycogenolysis and glycolysis.

Authors:  Richard Godfrey; Ros Quinlivan
Journal:  Nat Rev Neurol       Date:  2016-05-27       Impact factor: 42.937

2.  Skeletal and cardiac muscle involvement in children with glycogen storage disease type III.

Authors:  Engy A Mogahed; Marian Y Girgis; Rodina Sobhy; Hala Elhabashy; Osama M Abdelaziz; Hanaa El-Karaksy
Journal:  Eur J Pediatr       Date:  2015-05-07       Impact factor: 3.183

Review 3.  Treatment Opportunities in Patients With Metabolic Myopathies.

Authors:  Mette Cathrine Ørngreen; John Vissing
Journal:  Curr Treat Options Neurol       Date:  2017-09-21       Impact factor: 3.598

Review 4.  Exercise in muscle glycogen storage diseases.

Authors:  Nicolai Preisler; Ronald G Haller; John Vissing
Journal:  J Inherit Metab Dis       Date:  2014-10-18       Impact factor: 4.982

Review 5.  Physical therapy assessment and whole-body magnetic resonance imaging findings in children with glycogen storage disease type IIIa: A clinical study and review of the literature.

Authors:  Anna Paschall; Aleena A Khan; Syed Faaiz Enam; Tracy Boggs; Ghada Hijazi; Michael Bowling; Stephanie Austin; Laura E Case; Priya Kishnani
Journal:  Mol Genet Metab       Date:  2021-10-09       Impact factor: 4.797

6.  A New Perspective on the Quality of Life of Children with Glycogen Storage Diseases.

Authors:  Gihan Ahmed Sobhy; Mortada El-Shabrawi; Heba Safar
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2022-07-06

Review 7.  Dietary management in glycogen storage disease type III: what is the evidence?

Authors:  Terry G J Derks; G Peter A Smit
Journal:  J Inherit Metab Dis       Date:  2014-08-28       Impact factor: 4.982

8.  Glycogen storage disease type III: modified Atkins diet improves myopathy.

Authors:  Sebene Mayorandan; Uta Meyer; Hans Hartmann; Anibh Martin Das
Journal:  Orphanet J Rare Dis       Date:  2014-11-28       Impact factor: 4.123

Review 9.  Glycogen metabolism in humans.

Authors:  María M Adeva-Andany; Manuel González-Lucán; Cristóbal Donapetry-García; Carlos Fernández-Fernández; Eva Ameneiros-Rodríguez
Journal:  BBA Clin       Date:  2016-02-27

10.  Genetic analysis and clinical assessment of four patients with Glycogen Storage Disease Type IIIa in China.

Authors:  Yu Zhang; Mingming Xu; Xiaoxia Chen; Aijuan Yan; Guoyong Zhang; Zhenguo Liu; Wenjuan Qiu
Journal:  BMC Med Genet       Date:  2018-04-04       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.